LYTIX BIOPHARMA ASA LYTIX ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE

Lytix Biopharma ASA: Ex. subsequent offering

18. November 2026 kl. 02:04

Oslo, Norway, 18 November 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma ASA ("Lytix Biopharma" or the "Company") today regarding the successful completion of a private placement (the "Private Placement") and a retail offering (the "Retail Offering") of new shares (the "Offer Shares") raising NOK 80 million in gross proceeds, and a subsequent offering of new shares, at the same price as in the Private Placement and Retail Offering, NOK 8.00 per share (the "Subsequent Offering").

The Subsequent Offering will be directed towards existing shareholders in the Company as of 17 November 2026 (as registered in the VPS on 19 November 2026), subject to the limitations and conditions set out in the stock exchange announcement including key information about the Subsequent Offering. The shares in Lytix Biopharma will accordingly be traded exclusive of the right to participate in the Subsequent Offering from and including today.

Ex. date: 18 November 2026

This information is published in accordance with the requirements of the Continuing Obligations.

For further information, please contact: Gjest Breistein, CFO gjest.breistein@lytixbiopharma.com +47 952 60 512

About Lytix Biopharma Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to effectively prime durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker LYTIX.